Avalyn Pharma (AVLN) director discloses 64,919-share stock option grant details

Rhea-AI Filing Summary

Avalyn Pharma Inc. director Heather D. Turner reported her initial equity holdings. The filing shows a stock option giving her the right to buy 64,919 shares of common stock at an exercise price of $5.58 per share, expiring on October 29, 2034.

According to the vesting terms, 1/8 of the shares underlying this option vest in substantially equal quarterly installments on each quarterly anniversary of October 30, 2024, as long as she continues in service. This is a compensation-related option holding, not a buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Turner Heather D

Role null

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 64,919 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Underlying option shares: 64,919 shares Exercise price: $5.58/share Shares following transaction: 64,919 shares +3 more

6 metrics

Underlying option shares 64,919 shares Common stock underlying stock option holding

Exercise price $5.58/share Stock option exercise price

Shares following transaction 64,919 shares Total underlying shares reported for the option

Option expiration date October 29, 2034 Final date to exercise the reported option

Vesting fraction 1/8 of shares Portion of option vesting in quarterly installments

Vesting start reference date October 30, 2024 Quarterly anniversary date used for vesting schedule

Key Terms

Stock Option (right to buy), underlying security, exercise price, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

underlying security financial

"underlying_security_title: Common Stock"

exercise price financial

"conversion_or_exercise_price: 5.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying this option vest and become exercisable in substantially equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2034-10-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Turner Heather D

(Last) (First) (Middle)

105 W FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/29/2026

3. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	10/29/2034	Common Stock	64,919	$5.58	D

Explanation of Responses:

1. 1/8th of the shares underlying this option vest and become exercisable in substantially equal quarterly installments on each quarterly anniversary of October 30, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Douglas Carlson	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position did Heather D. Turner report in Avalyn Pharma (AVLN)?

Heather D. Turner reported holding a stock option on Avalyn Pharma common stock. The option covers 64,919 underlying shares at an exercise price of $5.58, providing equity-based compensation linked to her service as a director on the company’s board.

Is the Avalyn Pharma (AVLN) Form 3 a buy or sell by Heather Turner?

The Avalyn Pharma Form 3 does not report a buy or sell transaction. It discloses Heather Turner’s existing stock option holding as an insider, detailing the number of underlying shares, exercise price, and vesting schedule as part of her compensation package.

What are the key terms of Heather Turner’s Avalyn Pharma (AVLN) stock option?

Her Avalyn Pharma stock option has an exercise price of $5.58 per share and expires on October 29, 2034. It covers 64,919 underlying common shares, subject to a time-based vesting schedule tied to continued service as a director.

How does Heather Turner’s Avalyn Pharma (AVLN) option vest over time?

One-eighth of the option’s underlying shares vest in substantially equal quarterly installments. Vesting occurs on each quarterly anniversary of October 30, 2024, provided Heather Turner continues to serve, gradually increasing the portion of the option that becomes exercisable.

What does the Avalyn Pharma (AVLN) Form 3 reveal about derivative holdings?

The Form 3 shows a derivative holding: a stock option on Avalyn Pharma common stock. It lists 64,919 underlying shares, a $5.58 exercise price, and an October 29, 2034 expiration, indicating a long-dated equity incentive rather than an immediate market transaction.